These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 14649216)

  • 21. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
    Yue DK; Brooks B
    Med J Aust; 1993 Jul; 159(2):76-8. PubMed ID: 8336605
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment for diabetic neuropathy.
    Watkins PJ
    Diabet Med; 1996 Dec; 13(12):1007-8. PubMed ID: 8973880
    [No Abstract]   [Full Text] [Related]  

  • 23. Aldose reductase inhibitors.
    Oka M; Kato N
    J Enzyme Inhib; 2001 Dec; 16(6):465-73. PubMed ID: 12164386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent clinical experience with aldose reductase inhibitors.
    Krans HM
    J Diabetes Complications; 1992; 6(1):39-44. PubMed ID: 1562757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Imidazolidine/thiazolidine-acetate aldose reductase inhibitors].
    Fresneau P
    Ann Pharm Fr; 2000 Dec; 58(6):392-404. PubMed ID: 11148374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA; Borja NL
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Charge density and electrostatic interactions of fidarestat, an inhibitor of human aldose reductase.
    Fournier B; Bendeif el-E; Guillot B; Podjarny A; Lecomte C; Jelsch C
    J Am Chem Soc; 2009 Aug; 131(31):10929-41. PubMed ID: 19594152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aldose reductase inhibitors and diabetic complications.
    Tomlinson DR; Willars GB; Carrington AL
    Pharmacol Ther; 1992; 54(2):151-94. PubMed ID: 1438531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex.
    Petrova T; Steuber H; Hazemann I; Cousido-Siah A; Mitschler A; Chung R; Oka M; Klebe G; El-Kabbani O; Joachimiak A; Podjarny A
    J Med Chem; 2005 Sep; 48(18):5659-65. PubMed ID: 16134934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
    Greene DA
    J Diabetes Complications; 1992; 6(1):35-8. PubMed ID: 1562756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
    Kell J
    Curr Opin Investig Drugs; 2007 Jun; 8(6):485-92. PubMed ID: 17621879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fidarestat improves cardiomyocyte contractile function in db/db diabetic obese mice through a histone deacetylase Sir2-dependent mechanism.
    Dong F; Ren J
    J Hypertens; 2007 Oct; 25(10):2138-47. PubMed ID: 17885559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
    Wright M; Hill S; Slaney MA
    Med J Aust; 1994 Jan; 160(1):45. PubMed ID: 8123141
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluation of ranirestat for the treatment of diabetic neuropathy.
    Giannoukakis N
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1051-9. PubMed ID: 24785785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography.
    Oka M; Matsumoto Y; Sugiyama S; Tsuruta N; Matsushima M
    J Med Chem; 2000 Jun; 43(12):2479-83. PubMed ID: 10882376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
    Roy TM; Broadstone VL; Peterson HR; Snider HL; Cyrus J; Fell R; Rothchild AH; Samols E; Pfeifer MA
    Diabetes Res Clin Pract; 1990; 10(1):91-7. PubMed ID: 2123430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor.
    El-Kabbani O; Darmanin C; Oka M; Schulze-Briese C; Tomizaki T; Hazemann I; Mitschler A; Podjarny A
    J Med Chem; 2004 Aug; 47(18):4530-7. PubMed ID: 15317464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
    El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
    Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of diabetic neuropathy and neuropathic pain: how far have we come?
    Ziegler D
    Diabetes Care; 2008 Feb; 31 Suppl 2():S255-61. PubMed ID: 18227494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
    Florkowski CM
    Med J Aust; 1993 Nov; 159(10):711-2. PubMed ID: 8110237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.